{"id":"hu-014-inj","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Vomiting"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Injection site reactions"}]},"_chembl":{"chemblId":"CHEMBL3693919","moleculeType":"Small molecule","molecularWeight":"597.14"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"HU-014 binds to and activates the glucagon-like peptide-1 (GLP-1) receptor on pancreatic beta cells, stimulating glucose-dependent insulin secretion. It also suppresses glucagon release and slows gastric emptying, collectively reducing postprandial and fasting blood glucose levels. The long-acting formulation allows for less frequent dosing compared to short-acting GLP-1 agonists.","oneSentence":"HU-014 is a long-acting GLP-1 receptor agonist that enhances insulin secretion and reduces glucagon levels to improve glycemic control.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:46:14.538Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT05289921","phase":"PHASE3","title":"To Evaluate HU-014 in the Treatment of Post Stroke Upper Limb","status":"COMPLETED","sponsor":"Huons Co., Ltd.","startDate":"2022-03-04","conditions":"Post Stroke Upper Limb Spasticity","enrollment":198},{"nctId":"NCT04415346","phase":"PHASE1","title":"A Single Center, Phase I Clinical Trial to Evaluate the Safety of LIZTOX Inj in the Treatment of Post Stroke Upper Limb Spasticity","status":"UNKNOWN","sponsor":"Huons Co., Ltd.","startDate":"2019-11-06","conditions":"Post Stroke Upper Limb Spasticity","enrollment":13},{"nctId":"NCT04081402","phase":"PHASE3","title":"A Phase 1/3 Clinical Trial to Evaluate the Safety and Efficacy of HUTOX Compared to Botox® in Subjects With Moderate to Severe Crow's Feet Lines","status":"UNKNOWN","sponsor":"Huons Co., Ltd.","startDate":"2018-11-01","conditions":"Crow's Feet Lines","enrollment":290},{"nctId":"NCT02961673","phase":"PHASE1, PHASE2","title":"The Safety and Efficacy Study of HU-014 Versus Botox® in Subject With Moderate to Severe Glabellar Lines","status":"COMPLETED","sponsor":"Huons Co., Ltd.","startDate":"2016-09","conditions":"Glabellar Lines","enrollment":57}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"HU-014 Inj","genericName":"HU-014 Inj","companyName":"Huons Co., Ltd.","companyId":"huons-co-ltd","modality":"Biologic","firstApprovalDate":"","aiSummary":"HU-014 is a long-acting GLP-1 receptor agonist that enhances insulin secretion and reduces glucagon levels to improve glycemic control. Used for Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}